Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness

J Infect Dis. 2020 Sep 2;222(Suppl 5):S365-S375. doi: 10.1093/infdis/jiaa207.

Abstract

Background: The effectiveness of hepatitis C testing and linkage-to-care (LTC) is poorly characterized in low-resource jurisdictions facing gaps in harm reduction, including illegality of syringe exchange services. Effectiveness of a community-based test/LTC program was evaluated in Alabama.

Methods: In 2016-2018, shelters, drug treatment centers (DTCs), AIDS organizations, and Federally Qualified Health Centers (FQHCs) engaged in screening/LTC. A coordinator navigated individuals to confirm viremia and link to substance use treatment or primary care with hepatitis C prescribers.

Results: Point-of-care (POC) tested 4293 individuals (10% [427] antibody-positive, 71% [299/419] RNA performed, 80% [241/299] viremia confirmed) and 93% linked to care (225/241). Electronic medical record (EMR)-based reflex strategy screened 4654 (15% [679] antibody positive, 99% [670/679] RNA performed, 64% [433/679] viremia confirmed) and 85% linked to care (368/433). We observed higher odds of RNA confirmation in EMR-based reflex versus POC (OR, 2.07; P < .0001) and higher odds of LTC in EMR-based reflex versus POC (OR, 1.51; P < .0001). Overall, 53% individuals tested were nonbaby boomers.

Conclusions: In Alabama, screening at high-risk settings identified significant hepatitis C burden and reflex testing outperformed point-of-care linkage indicators. Colocating testing in DTCs and treatment in FQHCs provided key LTC venues to at-risk younger groups.

Keywords: hepatitis C virus; Alabama; injection drug use; linkage to care; prevalence; screening.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alabama / epidemiology
  • Community Health Services / organization & administration
  • Community Health Services / statistics & numerical data*
  • Cost of Illness*
  • Counseling / organization & administration
  • Counseling / statistics & numerical data
  • Drug Users / statistics & numerical data
  • Female
  • Hepacivirus / genetics
  • Hepacivirus / immunology
  • Hepacivirus / isolation & purification
  • Hepatitis C / diagnosis
  • Hepatitis C / epidemiology*
  • Hepatitis C / therapy
  • Hepatitis C / transmission
  • Hepatitis C Antibodies / isolation & purification
  • Humans
  • Male
  • Mass Screening / organization & administration
  • Mass Screening / statistics & numerical data*
  • Middle Aged
  • Point-of-Care Testing / organization & administration
  • Point-of-Care Testing / statistics & numerical data
  • Prospective Studies
  • RNA, Viral / isolation & purification
  • Risk Factors
  • Substance Abuse, Intravenous / complications*
  • Substance Abuse, Intravenous / rehabilitation
  • Vulnerable Populations / statistics & numerical data

Substances

  • Hepatitis C Antibodies
  • RNA, Viral